前瞻性随机双盲研究:68Ga-NODAGA-LM3与68Ga-DOTA-LM3在分化良好神经内分泌肿瘤患者中的诊断效能评估及与68Ga-DOTATATE的比较
本研究前瞻性随机双盲纳入40例分化良好神经内分泌肿瘤患者,分两组分别行68Ga-NODAGA-LM3或68Ga-DOTA-LM3 PET/CT并与68Ga-DOTATATE对比。两种拮抗剂在病灶检出上均优于68Ga-DOTATATE,68Ga-NODAGA-LM3肿瘤摄取和靶本比显著更高,68Ga-DOTA-LM3摄取相当但靶本比更高。
要点
- 两种拮抗剂在病灶检出(病灶水平和患者水平)均优于激动剂68Ga-DOTATATE。
- 68Ga-NODAGA-LM3肿瘤摄取(中位SUVmax 29.1 vs 21.6)和靶本比(中位肿瘤/肝比5.0 vs 2.9)显著高于68Ga-DOTATATE。
- 68Ga-DOTA-LM3摄取与68Ga-DOTATATE相当(中位SUVmax 16.1 vs 17.8,P=0.714),靶本比更高(中位肿瘤/肝比5.2 vs 2.1)。
核心结论
- 68Ga-NODAGA-LM3和68Ga-DOTA-LM3均为有前景的SSTR2拮抗剂,诊断效能优于激动剂68Ga-DOTATATE。
研究设计与样本
- 前瞻性随机双盲研究,共纳入40例分化良好神经内分泌肿瘤患者,A组和B组各20例。
- A组第1天行全身68Ga-NODAGA-LM3 PET/CT、第2天行68Ga-DOTATATE PET/CT;B组第1天行全身68Ga-DOTA-LM3 PET/CT、第2天行68Ga-DOTATATE PET/CT。
- 比较正常器官生物分布、病灶检出能力和肿瘤摄取。
主要发现
- 68Ga-NODAGA-LM3的正常器官分布模式与68Ga-DOTATATE相似。
- 68Ga-DOTA-LM3在几乎所有正常器官中的摄取显著低于68Ga-DOTATATE。
- 68Ga-NODAGA-LM3和68Ga-DOTA-LM3在病灶水平和患者水平比较中病灶检出均优于68Ga-DOTATATE。
- 68Ga-NODAGA-LM3较68Ga-DOTATATE肿瘤摄取显著更高(中位SUVmax 29.1 vs 21.6,P<0.05),靶本比显著更高(中位肿瘤/肝比5.0 vs 2.9,P<0.05)。
- 68Ga-DOTA-LM3较68Ga-DOTATATE肿瘤摄取相当(中位SUVmax 16.1 vs 17.8,P=0.714),靶本比更高(中位肿瘤/肝比5.2 vs 2.1,P<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study is to evaluate the diagnostic efficacy of 68 Ga-NODAGA-LM3 and 68 Ga-DOTA-LM3 and compare them with 68 Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors. METHODS: Patients were prospectively recruited and equally randomized into two arms: Arm A, patients would undergo a whole-body 68 Ga-NODAGA-LM3 PET/CT scan on the 1st day and 68 Ga-DOTATATE PET/CT scan on the 2nd day; Arm B, patients would undergo a whole-body 68 Ga-DOTA-LM3 PET/CT scan on the 1st day and 68 Ga-DOTATATE PET/CT scan on the 2nd day. Biodistribution in normal organs, lesion detection ability, and tumor uptake were compared between antagonist and agonist in each arm. RESULTS: A total of 40 patients with well-differentiated NETs, 20 in each arm, were recruited in the study. 68 Ga-NODAGA-LM3 showed a similar pattern as 68 Ga-DOTATATE, while 68 Ga-DOTA-LM3 demonstrated significantly lower uptake in almost all normal organs compared to 68 Ga-DOTATATE. Both 68 Ga-NODAGA-LM3 and 68 Ga-DOTA-LM3 showed superiority in lesion detection compared to 68 Ga-DOTATATE on lesion-based and patient-based comparison. 68 Ga-NODAGA-LM3 showed a significantly higher tumor uptake (median SUVmax 29.1 versus 21.6, P < 0.05) and tumor-to-background ratio (median tumor-to-liver ratio 5.0 versus 2.9, P < 0.05) compared to 68 Ga-DOTATATE. 68 Ga-DOTA-LM3 showed comparable uptake (median SUVmax 16.1 versus 17.8, P = 0.714) and higher tumor-to-background ratio (median tumor-to-liver ratio 5.2 versus 2.1, P < 0.05). CONCLUSION: Both 68 Ga-NODAGA-LM3 and 68 Ga-DOTA-LM3 are promising SSTR2 antagonists for neuroendocrine tumors. They demonstrated superiority in diagnostic efficacy compared to agonist 68 Ga-DOTATATE. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04318561.
引用
- Zhu W, Jia R, Yang Q, et al. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2021. PMID: 34874478. doi:10.1007/s00259-021-05512-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。